Clinical trial designs incorporating predictive biomarkers

Lindsay A. Renfro, Himel Mallick, Ming Wen An, Daniel J. Sargent, Sumithra J Mandrekar

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Development of oncologic therapies has traditionally been performed in a sequence of clinical trials intended to assess safety (phase I), preliminary efficacy (phase II), and improvement over the standard of care (phase III) in homogeneous (in terms of tumor type and disease stage) patient populations. As cancer has become increasingly understood on the molecular level, newer "targeted" drugs that inhibit specific cancer cell growth and survival mechanisms have increased the need for new clinical trial designs, wherein pertinent questions on the relationship between patient biomarkers and response to treatment can be answered. Herein, we review the clinical trial design literature from initial to more recently proposed designs for targeted agents or those treatments hypothesized to have enhanced effectiveness within patient subgroups (e.g., those with a certain biomarker value or who harbor a certain genetic tumor mutation). We also describe a number of real clinical trials where biomarker-based designs have been utilized, including a discussion of their respective advantages and challenges. As cancers become further categorized and/or reclassified according to individual patient and tumor features, we anticipate a continued need for novel trial designs to keep pace with the changing frontier of clinical cancer research.

Original languageEnglish (US)
Pages (from-to)74-82
Number of pages9
JournalCancer Treatment Reviews
Volume43
DOIs
StatePublished - 2016

Fingerprint

Biomarkers
Clinical Trials
Neoplasms
Standard of Care
Cell Survival
Therapeutics
Safety
Mutation
Growth
Research
Pharmaceutical Preparations
Population

Keywords

  • Adaptive trial design
  • Bayesian adaptive design
  • Biomarker-based design
  • Clinical trial design
  • Enrichment designs
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Clinical trial designs incorporating predictive biomarkers. / Renfro, Lindsay A.; Mallick, Himel; An, Ming Wen; Sargent, Daniel J.; Mandrekar, Sumithra J.

In: Cancer Treatment Reviews, Vol. 43, 2016, p. 74-82.

Research output: Contribution to journalArticle

Renfro, Lindsay A. ; Mallick, Himel ; An, Ming Wen ; Sargent, Daniel J. ; Mandrekar, Sumithra J. / Clinical trial designs incorporating predictive biomarkers. In: Cancer Treatment Reviews. 2016 ; Vol. 43. pp. 74-82.
@article{a91568205cb24823a56d3bd8ce5ae026,
title = "Clinical trial designs incorporating predictive biomarkers",
abstract = "Development of oncologic therapies has traditionally been performed in a sequence of clinical trials intended to assess safety (phase I), preliminary efficacy (phase II), and improvement over the standard of care (phase III) in homogeneous (in terms of tumor type and disease stage) patient populations. As cancer has become increasingly understood on the molecular level, newer {"}targeted{"} drugs that inhibit specific cancer cell growth and survival mechanisms have increased the need for new clinical trial designs, wherein pertinent questions on the relationship between patient biomarkers and response to treatment can be answered. Herein, we review the clinical trial design literature from initial to more recently proposed designs for targeted agents or those treatments hypothesized to have enhanced effectiveness within patient subgroups (e.g., those with a certain biomarker value or who harbor a certain genetic tumor mutation). We also describe a number of real clinical trials where biomarker-based designs have been utilized, including a discussion of their respective advantages and challenges. As cancers become further categorized and/or reclassified according to individual patient and tumor features, we anticipate a continued need for novel trial designs to keep pace with the changing frontier of clinical cancer research.",
keywords = "Adaptive trial design, Bayesian adaptive design, Biomarker-based design, Clinical trial design, Enrichment designs, Targeted therapies",
author = "Renfro, {Lindsay A.} and Himel Mallick and An, {Ming Wen} and Sargent, {Daniel J.} and Mandrekar, {Sumithra J}",
year = "2016",
doi = "10.1016/j.ctrv.2015.12.008",
language = "English (US)",
volume = "43",
pages = "74--82",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Clinical trial designs incorporating predictive biomarkers

AU - Renfro, Lindsay A.

AU - Mallick, Himel

AU - An, Ming Wen

AU - Sargent, Daniel J.

AU - Mandrekar, Sumithra J

PY - 2016

Y1 - 2016

N2 - Development of oncologic therapies has traditionally been performed in a sequence of clinical trials intended to assess safety (phase I), preliminary efficacy (phase II), and improvement over the standard of care (phase III) in homogeneous (in terms of tumor type and disease stage) patient populations. As cancer has become increasingly understood on the molecular level, newer "targeted" drugs that inhibit specific cancer cell growth and survival mechanisms have increased the need for new clinical trial designs, wherein pertinent questions on the relationship between patient biomarkers and response to treatment can be answered. Herein, we review the clinical trial design literature from initial to more recently proposed designs for targeted agents or those treatments hypothesized to have enhanced effectiveness within patient subgroups (e.g., those with a certain biomarker value or who harbor a certain genetic tumor mutation). We also describe a number of real clinical trials where biomarker-based designs have been utilized, including a discussion of their respective advantages and challenges. As cancers become further categorized and/or reclassified according to individual patient and tumor features, we anticipate a continued need for novel trial designs to keep pace with the changing frontier of clinical cancer research.

AB - Development of oncologic therapies has traditionally been performed in a sequence of clinical trials intended to assess safety (phase I), preliminary efficacy (phase II), and improvement over the standard of care (phase III) in homogeneous (in terms of tumor type and disease stage) patient populations. As cancer has become increasingly understood on the molecular level, newer "targeted" drugs that inhibit specific cancer cell growth and survival mechanisms have increased the need for new clinical trial designs, wherein pertinent questions on the relationship between patient biomarkers and response to treatment can be answered. Herein, we review the clinical trial design literature from initial to more recently proposed designs for targeted agents or those treatments hypothesized to have enhanced effectiveness within patient subgroups (e.g., those with a certain biomarker value or who harbor a certain genetic tumor mutation). We also describe a number of real clinical trials where biomarker-based designs have been utilized, including a discussion of their respective advantages and challenges. As cancers become further categorized and/or reclassified according to individual patient and tumor features, we anticipate a continued need for novel trial designs to keep pace with the changing frontier of clinical cancer research.

KW - Adaptive trial design

KW - Bayesian adaptive design

KW - Biomarker-based design

KW - Clinical trial design

KW - Enrichment designs

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84962829151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962829151&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.12.008

DO - 10.1016/j.ctrv.2015.12.008

M3 - Article

VL - 43

SP - 74

EP - 82

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -